2020
Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis
Risch HA. Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis. American Journal Of Epidemiology 2020, 189: 1218-1226. PMID: 32458969, PMCID: PMC7546206, DOI: 10.1093/aje/kwaa093.Peer-Reviewed Original ResearchConceptsOutpatient treatmentHigh-risk COVID-19 patientsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2High-risk patientsUse of hydroxychloroquineMultiple comorbid conditionsCOVID-19 patientsEfficacy of hydroxychloroquineEarly outpatient treatmentStandard of careSyndrome coronavirus 2Mild effectivenessOutpatient diseasesOutpatient illnessOutpatient trialSuch patientsSymptomatic diseaseComorbid conditionsCoronavirus 2Hospitalized inpatientsClinical trialsCandidate medicationsHydroxychloroquine
2009
Molecular markers and death from prostate cancer.
Concato J, Jain D, Uchio E, Risch H, Li WW, Wells CK. Molecular markers and death from prostate cancer. Annals Of Internal Medicine 2009, 150: 595-603. PMID: 19414838, DOI: 10.7326/0003-4819-150-9-200905050-00005.Peer-Reviewed Original ResearchConceptsProstate-specific antigen levelProstate cancerLong-term riskAntigen levelsMicrovessel densityMedian prostate-specific antigen levelIncreased long-term riskVeterans Affairs Healthcare SystemIncident prostate cancerObservational cohort studyProportional hazards analysisTime of diagnosisHigher microvessel densityVeterans Health AdministrationBcl-2Years of ageProstate cancer biopsiesClinical care recordsClinical characteristicsCohort studyPatient ageMedian ageComorbid conditionsHistologic gradeResidual confounding